Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APC-5000
- Development stage
- Preclinical
- Lead developer
- Adamis Pharmaceuticals
- Administration
- Inhalation
01
Overview
APC-5000 is a respiratory drug candidate developed by Adamis Pharmaceuticals for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The drug is designed to be delivered using a dry powder inhaler (DPI) technology, known as Taper DPI, which Adamis Pharmaceuticals acquired or licensed from 3M. The development of APC-5000 is part of Adamis' pipeline products aimed at respiratory and allergy conditions.
Beyond the preview
Go deeper on APC-5000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APC-5000.